Clay Siegal, The Most Prominent Biotechnology Researcher

Human antibodies are at the heart of everything Seattle Genetics has been researching, manipulating and, eventually, packaging into medications since its inception in 1998. Just like Lego bricks, the influence of the antibodies of the company lies in their ability to bond with something else. The antibody supplies a toxic load into cancer cell to crush it from within. It is a strategy that can shoot Seattle Genetics into the great leagues.

Enjoying a market value of almost 10 billion dollars and a list of 900 members of staff, Seattle Genetics ranks as the most prominent biotech in the state of Washington. With outstanding ambitions to get ranked among the few corporations that advance from biotech to large pharmaceuticals, it invests profoundly in marketing and research and anticipates to add 200 more members of staff this year.

The firm’s flagship drug, Adcetris, treats Hodgkin lymphoma, which a type of cancer that affects the lymph system and it can spread quickly to other organs. If extensive tests underway prove affirmative, its sales will take off. The CEO, co-founder, president and chairman of Seattle Genetics, Clay Siegal says that the firm is an emerging multiproduct, oncology and global company. Pointing to the long list of medications in the company’s pipeline Siegal says that that’s enough evidence to show his desire to create a great firm rather than selling it to a more prominent corporation the way most of the biotech companies do.

Based in the United States, Dr. Clay Siegal is a biotechnology researcher and the Chief Executive Officer of Seattle Genetics. Siegal started the firm, and he has been operating it to impact the pharmaceuticals sector positively by producing a wide variety of drugs to treat cancer. Seattle Genetics is an innovative firm company committed to creating unique medicines that can assist in treating cancer patients throughout the world. The company has produced ADCs, which have significantly enhanced the rate of motility amongst cancer patients. The production and distribution of the drugs have been made much easier by working in partnership with some of the leading firms such as Genentech, Bayer, and Takeda Pharmaceutical Company.

Mr. Clay graduated with a Bachelor of Science in Zoology from the University of Maryland and is a Ph.D. holder in Genetics from George Washington University as well. His research undertakings at Seattle Genetics have considerably benefited the pharmaceuticals industry. Siegal has managed to get 15 patents for the medications he has produced. Dr.Clay Siegal has also published over 75 scientific books being used by scholars and professionals for reference.